Tags

Type your tag names separated by a space and hit enter

Souvenaid®: a new approach to management of early Alzheimer's disease.
J Nutr Health Aging 2014; 18(3):291-9JN

Abstract

Synaptic loss correlates closely with cognitive deficits in Alzheimer's disease and represents a new target for intervention. Souvenaid® is the first medical nutrition product to be designed to support synapse formation and function in early Alzheimer's disease, and has undergone an extensive, 12-year development programme. The relatively large amount of clinical data available for Souvenaid® is unusual for a medical nutrition product. Souvenaid® contains omega-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid), uridine (as uridine monophosphate) and choline which are nutritional precursors required for synaptic membrane phospholipid synthesis, together with phospholipids and other cofactors. Souvenaid® has demonstrated cognitive benefits in patients with mild Alzheimer's disease but not in patients with mild-to-moderate Alzheimer's disease. Two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in patients with mild Alzheimer's disease untreated with acetylcholinesterase inhibitors and/or memantine have demonstrated that Souvenaid® is well tolerated and improves episodic memory performance. The daily intake of Souvenaid® has not been associated with any harmful effects or interactions with medications and none are anticipated. The ongoing, 24-month, European Union-funded LipiDiDiet trial in subjects with prodromal Alzheimer's disease is evaluating the potential benefits of Souvenaid® on memory and in slowing progression to Alzheimer's dementia. If Souvenaid® induces synaptogenesis and improved synaptic function, it may provide benefits in other clinical conditions characterised by neurodegeneration. A number of trials are ongoing and planned to evaluate the potential wider benefits of Souvenaid®.

Authors+Show Affiliations

C Ritchie, Department of Medicine, Imperial College, London, UK, c.ritchie@imperial.ac.uk; npeaker@mednetconsult.co.uk.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24626757

Citation

Ritchie, C W., et al. "Souvenaid®: a New Approach to Management of Early Alzheimer's Disease." The Journal of Nutrition, Health & Aging, vol. 18, no. 3, 2014, pp. 291-9.
Ritchie CW, Bajwa J, Coleman G, et al. Souvenaid®: a new approach to management of early Alzheimer's disease. J Nutr Health Aging. 2014;18(3):291-9.
Ritchie, C. W., Bajwa, J., Coleman, G., Hope, K., Jones, R. W., Lawton, M., ... Passmore, P. (2014). Souvenaid®: a new approach to management of early Alzheimer's disease. The Journal of Nutrition, Health & Aging, 18(3), pp. 291-9. doi:10.1007/s12603-013-0411-2.
Ritchie CW, et al. Souvenaid®: a New Approach to Management of Early Alzheimer's Disease. J Nutr Health Aging. 2014;18(3):291-9. PubMed PMID: 24626757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Souvenaid®: a new approach to management of early Alzheimer's disease. AU - Ritchie,C W, AU - Bajwa,J, AU - Coleman,G, AU - Hope,K, AU - Jones,R W, AU - Lawton,M, AU - Marven,M, AU - Passmore,P, PY - 2014/3/15/entrez PY - 2014/3/15/pubmed PY - 2015/6/19/medline SP - 291 EP - 9 JF - The journal of nutrition, health & aging JO - J Nutr Health Aging VL - 18 IS - 3 N2 - Synaptic loss correlates closely with cognitive deficits in Alzheimer's disease and represents a new target for intervention. Souvenaid® is the first medical nutrition product to be designed to support synapse formation and function in early Alzheimer's disease, and has undergone an extensive, 12-year development programme. The relatively large amount of clinical data available for Souvenaid® is unusual for a medical nutrition product. Souvenaid® contains omega-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid), uridine (as uridine monophosphate) and choline which are nutritional precursors required for synaptic membrane phospholipid synthesis, together with phospholipids and other cofactors. Souvenaid® has demonstrated cognitive benefits in patients with mild Alzheimer's disease but not in patients with mild-to-moderate Alzheimer's disease. Two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in patients with mild Alzheimer's disease untreated with acetylcholinesterase inhibitors and/or memantine have demonstrated that Souvenaid® is well tolerated and improves episodic memory performance. The daily intake of Souvenaid® has not been associated with any harmful effects or interactions with medications and none are anticipated. The ongoing, 24-month, European Union-funded LipiDiDiet trial in subjects with prodromal Alzheimer's disease is evaluating the potential benefits of Souvenaid® on memory and in slowing progression to Alzheimer's dementia. If Souvenaid® induces synaptogenesis and improved synaptic function, it may provide benefits in other clinical conditions characterised by neurodegeneration. A number of trials are ongoing and planned to evaluate the potential wider benefits of Souvenaid®. SN - 1760-4788 UR - https://www.unboundmedicine.com/medline/citation/24626757/Souvenaid®:_a_new_approach_to_management_of_early_Alzheimer's_disease_ L2 - https://medlineplus.gov/alzheimersdisease.html DB - PRIME DP - Unbound Medicine ER -